Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, January 21st, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26.

Palvella Therapeutics Stock Performance

PVLA opened at $112.50 on Friday. The company has a fifty day moving average price of $103.11 and a two-hundred day moving average price of $88.18. The firm has a market capitalization of $1.33 billion, a PE ratio of -42.78 and a beta of -0.30. Palvella Therapeutics, Inc. has a 52 week low of $18.23 and a 52 week high of $151.18.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently made changes to their positions in PVLA. First Light Asset Management LLC bought a new position in Palvella Therapeutics during the third quarter worth about $33,949,000. Summit Partners Public Asset Management LLC increased its holdings in shares of Palvella Therapeutics by 1,016.0% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after acquiring an additional 354,525 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Palvella Therapeutics in the third quarter worth about $21,255,000. Vanguard Group Inc. raised its position in shares of Palvella Therapeutics by 202.0% during the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after purchasing an additional 330,847 shares during the period. Finally, State Street Corp raised its position in shares of Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares during the period. Institutional investors own 40.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PVLA. UBS Group reaffirmed a “buy” rating and set a $143.00 price objective on shares of Palvella Therapeutics in a research note on Monday, December 15th. BTIG Research raised their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Craig Hallum assumed coverage on Palvella Therapeutics in a research report on Thursday, December 4th. They set a “buy” rating and a $175.00 target price for the company. HC Wainwright upped their price target on Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $184.87.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.